Basnight Named ACNO, DCI Oncology Services, Wake County
Published
From the Duke Cancer Institute archives. Content may be out of date.
Ramona Basnight, DNP, RN, NEA-BC, has been appointed associate chief nursing officer for DCI Oncology Services, Wake County. She assumed her new role on July 18.
"Ramona is known to many of you, so it’s no surprise that she brings a wealth of oncology nursing leadership to the team, having previously served as interim associate chief nursing officer and clinical operations director for Ambulatory Care Services & Hospital-Based Clinics at Duke University Hospital; nurse manager of Operations for Duke Cancer Center Cary Radiation Oncology and Duke Cancer Center Cary; and nurse manager for women's cancers at Duke University Hospital," said Monica Cfarku, RN, MSN, BMTCN, CCM, NE-BC, assistant vice president and chief of Oncology Nursing Services, Duke Cancer Institute, in a written announcement to DCI faculty and staff welcoming Basnight.
Basnight obtained her Doctor of Nursing Practice from the University of North Carolina at Greensboro and is currently a post-doctorate scholar at Duke University School of Nursing. She is a certified Advanced Nurse Executive, a Master TeamSTEPPS Trainer, and Lean Six Sigma Green Belt. She has received multiple awards, most recently the 2022 Duke Friends of Nursing Award for Excellence in Nursing Leadership.
This video was posted in May 2022 by the Duke Friends of Nursing when Basnight received the Award for Excellence in Nursing Leadership. Nomination excerpts were posted along with the following message: "Throughout the Covid-19 pandemic, Ramona has been engaged in creating countless new processes and modifying existing ones. She has been instrumental in creating new places to deliver care that had never been necessary before, and ensuring that they were outfitted, supplied, staffed, and had everything needed for the mission they had been assigned. She did all this while ensuring all of the existing areas in her responsibility continued to function in a modified way to adapt to the threats to patient and staff safety that the pandemic created. Challenge after challenge presented itself and was overcome because of this nominee’s plasticity, critical thinking, and ability to use what she knew in different ways than had ever been necessary before."
Learn More about Ms. Basnight's Award for Excellence in Nursing Leadership
More than 300 patients, caregivers and family members gathered for the 2026 Genitourinary Cancers Community Education Event, an opportunity to learn directly from experts belonging to the Duke Cancer Institute’s Center for Prostate and Urologic Cancers. Presentations focused on longer, healthier lives for people living with GU cancers.The event brought together more than 23 specialists representing medical oncology, urology, radiation oncology, radiology, clinical psychology and cancer support. Speakers included Andrew Armstrong MD, Mike Abern MD, Hannah Fisher PhD, Jeff Gahan MD, Daniel George MD, Paul Koffer MD, Tim Dougherty MD, Diana Kozman MD, and Danielle Kruse MD, who shared their expertise on topics ranging from new treatments and clinical research to imaging, surgery and Duke’s multidisciplinary approach to cancer care.The keynote address was delivered by Robert M. Califf, MD, whose career has included leadership in clinical research at Duke and service as commissioner of the U.S. Food and Drug Administration. Califf spoke about “Clinical Research Improves Patient Care,” highlighting the connection between rigorous research, advances in treatment and the care patients receive. His career at Duke included leadership of the Duke Clinical Research Institute, and his work has spanned clinical research, patient care and health policy.The program also recognized that living well with cancer involves more than medical treatment. Hannah Fischer, MD led an interactive session exploring mind/body approaches to coping with cancer. Keegan Zavodnik discussed nutrition and diets for people living with cancer, while Alexis Monks addressed the role of fitness and physical activity. These sessions complemented the medical presentations with practical approaches to supporting patients throughout their cancer journeys.One session, called The Great Wait, focused on building a personal philosophy for living life to the fullest in the post-treatment phase of cancer, when a person is in remission. “Some of you in the audience today probably have only a 5% chance of your cancer recurring, but you’re still living every day in fear. Instead, go out and enjoy life. Let us tell you if it is ever time to worry again,” said Dan George, MD, who gave the talk along with Sarah Wood, MSN ANP-CH.The event's emphasis on hearing from a variety of cancer experts, with opportunities to interact with those experts, was reflected strongly in post-event survey responses from attendees.One participant wrote, “It’s a gift to the community. Love hearing about the latest developments in research particularly.” Another shared, “This event has been life changing for me. A cancer diagnosis for my husband was devastating. This event help to enlighten, encourage and ground me. I will be forever grateful for that.” Another said: “I appreciated the warm, respectfulness, and candidness of the healthcare professionals.”For others, the opportunity to connect with fellow patients was just as meaningful: “What I liked best is the connection with patients and learning their stories.” Another said “I appreciated the community-building nature of this event. It’s very gratifying to see the GU Cancer Center making this effort to engage us beyond the clinic visits.”Held for the second time at North Carolina Central’s student center, the event was made possible through the efforts of 13 volunteers from the GU Patient Advisory Council, who staffed registration tables, welcomed attendees at the entrance and helped direct patients and families from parking areas to the event hall. More than 65 people gave scholarships or made donations so that anyone could attend for free.Other expert presenters: Sarah Wood MSN ANP-CH, Sundhar Ramalingam MD, Jordan Infield MD, Michael Superdock MD, Dominic LaBella MD, Christopher Hoimes DO, Mike Harrison MD, Joe Park MD, and Dillon Cockrell MD, Jeff Shevach MD, Matt Labriola MD, and Jennifer Freedman, PhD.
A Duke-led study published in iScience provides new insights into the tumor microenvironment of brain metastases, identifying distinct macrophage populations associated with patient survival and highlighting potential targets for future therapeutic intervention.Brain metastases remain a significant clinical challenge across multiple tumor types, including breast cancer, lung cancer, and melanoma. Despite advances in systemic therapies and local treatment approaches, outcomes remain poor for many patients, underscoring the need for a deeper understanding of the biological mechanisms driving disease progression.Using an integrated multi-omic approach, investigators analyzed 23 human brain metastasis specimens through single-nucleus RNA sequencing and spatial transcriptomic profiling. The study leveraged these complementary technologies to characterize cellular heterogeneity within the tumor microenvironment and define spatial relationships between immune and tumor cell populations.The analysis revealed substantial macrophage heterogeneity and demonstrated that macrophage-associated transcriptional programs differ significantly between patients with favorable and unfavorable survival outcomes. Specifically, inflammatory macrophage populations localized at the tumor boundary were associated with improved survival, while macrophage populations characterized by extracellular matrix remodeling signatures and TGFβ1 expression were associated with poorer outcomes.These findings suggest that distinct macrophage subtypes may play context-dependent roles in brain metastatic progression, functioning as either tumor-restrictive or tumor-supportive components of the microenvironment. The results further emphasize the importance of spatial cellular organization in shaping disease biology and clinical outcomes.Importantly, the study extends current understanding of immune-tumor interactions in brain metastases by linking specific macrophage subtypes and locations within the tumor ecosystem to survival-associated phenotypes. The identification of these distinct cellular programs may provide a framework for the development of novel therapeutic strategies aimed at modulating macrophage function or disrupting protumor signaling networks within the metastatic niche.As the incidence of brain metastases continues to increase and therapeutic resistance remains a critical barrier to long-term disease control, these findings represent an important step toward the development of more precise, microenvironment-directed treatment approaches. Further investigation will be needed to validate these observations and assess their translational potential in prospective clinical studies.This work was a joint research collaboration among Duke Center for Brain and Spine Metastasis (DCBSM) members: Dr. Ann Marie Pendergast (Department of Pharmacology and Cancer Biology, Duke University School of Medicine), Dr. Carey Anders (Department of Medicine, Division of Medical Oncology), and Dr. Simon Gregory (Department of Neurosurgery, and Duke Molecular Physiology Institute), and first-author Dr. Aaditya Khatri (Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University School of Medicine).
More than 300 patients, caregivers and family members gathered for the 2026 Genitourinary Cancers Community Education Event, an opportunity to learn directly from experts belonging to the Duke Cancer Institute’s Center for Prostate and Urologic Cancers. Presentations focused on longer, healthier lives for people living with GU cancers.The event brought together more than 23 specialists representing medical oncology, urology, radiation oncology, radiology, clinical psychology and cancer support. Speakers included Andrew Armstrong MD, Mike Abern MD, Hannah Fisher PhD, Jeff Gahan MD, Daniel George MD, Paul Koffer MD, Tim Dougherty MD, Diana Kozman MD, and Danielle Kruse MD, who shared their expertise on topics ranging from new treatments and clinical research to imaging, surgery and Duke’s multidisciplinary approach to cancer care.The keynote address was delivered by Robert M. Califf, MD, whose career has included leadership in clinical research at Duke and service as commissioner of the U.S. Food and Drug Administration. Califf spoke about “Clinical Research Improves Patient Care,” highlighting the connection between rigorous research, advances in treatment and the care patients receive. His career at Duke included leadership of the Duke Clinical Research Institute, and his work has spanned clinical research, patient care and health policy.The program also recognized that living well with cancer involves more than medical treatment. Hannah Fischer, MD led an interactive session exploring mind/body approaches to coping with cancer. Keegan Zavodnik discussed nutrition and diets for people living with cancer, while Alexis Monks addressed the role of fitness and physical activity. These sessions complemented the medical presentations with practical approaches to supporting patients throughout their cancer journeys.One session, called The Great Wait, focused on building a personal philosophy for living life to the fullest in the post-treatment phase of cancer, when a person is in remission. “Some of you in the audience today probably have only a 5% chance of your cancer recurring, but you’re still living every day in fear. Instead, go out and enjoy life. Let us tell you if it is ever time to worry again,” said Dan George, MD, who gave the talk along with Sarah Wood, MSN ANP-CH.The event's emphasis on hearing from a variety of cancer experts, with opportunities to interact with those experts, was reflected strongly in post-event survey responses from attendees.One participant wrote, “It’s a gift to the community. Love hearing about the latest developments in research particularly.” Another shared, “This event has been life changing for me. A cancer diagnosis for my husband was devastating. This event help to enlighten, encourage and ground me. I will be forever grateful for that.” Another said: “I appreciated the warm, respectfulness, and candidness of the healthcare professionals.”For others, the opportunity to connect with fellow patients was just as meaningful: “What I liked best is the connection with patients and learning their stories.” Another said “I appreciated the community-building nature of this event. It’s very gratifying to see the GU Cancer Center making this effort to engage us beyond the clinic visits.”Held for the second time at North Carolina Central’s student center, the event was made possible through the efforts of 13 volunteers from the GU Patient Advisory Council, who staffed registration tables, welcomed attendees at the entrance and helped direct patients and families from parking areas to the event hall. More than 65 people gave scholarships or made donations so that anyone could attend for free.Other expert presenters: Sarah Wood MSN ANP-CH, Sundhar Ramalingam MD, Jordan Infield MD, Michael Superdock MD, Dominic LaBella MD, Christopher Hoimes DO, Mike Harrison MD, Joe Park MD, and Dillon Cockrell MD, Jeff Shevach MD, Matt Labriola MD, and Jennifer Freedman, PhD.
A Duke-led study published in iScience provides new insights into the tumor microenvironment of brain metastases, identifying distinct macrophage populations associated with patient survival and highlighting potential targets for future therapeutic intervention.Brain metastases remain a significant clinical challenge across multiple tumor types, including breast cancer, lung cancer, and melanoma. Despite advances in systemic therapies and local treatment approaches, outcomes remain poor for many patients, underscoring the need for a deeper understanding of the biological mechanisms driving disease progression.Using an integrated multi-omic approach, investigators analyzed 23 human brain metastasis specimens through single-nucleus RNA sequencing and spatial transcriptomic profiling. The study leveraged these complementary technologies to characterize cellular heterogeneity within the tumor microenvironment and define spatial relationships between immune and tumor cell populations.The analysis revealed substantial macrophage heterogeneity and demonstrated that macrophage-associated transcriptional programs differ significantly between patients with favorable and unfavorable survival outcomes. Specifically, inflammatory macrophage populations localized at the tumor boundary were associated with improved survival, while macrophage populations characterized by extracellular matrix remodeling signatures and TGFβ1 expression were associated with poorer outcomes.These findings suggest that distinct macrophage subtypes may play context-dependent roles in brain metastatic progression, functioning as either tumor-restrictive or tumor-supportive components of the microenvironment. The results further emphasize the importance of spatial cellular organization in shaping disease biology and clinical outcomes.Importantly, the study extends current understanding of immune-tumor interactions in brain metastases by linking specific macrophage subtypes and locations within the tumor ecosystem to survival-associated phenotypes. The identification of these distinct cellular programs may provide a framework for the development of novel therapeutic strategies aimed at modulating macrophage function or disrupting protumor signaling networks within the metastatic niche.As the incidence of brain metastases continues to increase and therapeutic resistance remains a critical barrier to long-term disease control, these findings represent an important step toward the development of more precise, microenvironment-directed treatment approaches. Further investigation will be needed to validate these observations and assess their translational potential in prospective clinical studies.This work was a joint research collaboration among Duke Center for Brain and Spine Metastasis (DCBSM) members: Dr. Ann Marie Pendergast (Department of Pharmacology and Cancer Biology, Duke University School of Medicine), Dr. Carey Anders (Department of Medicine, Division of Medical Oncology), and Dr. Simon Gregory (Department of Neurosurgery, and Duke Molecular Physiology Institute), and first-author Dr. Aaditya Khatri (Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Duke University School of Medicine).
